주사용 세포독성약물 시장 : 약제 클래스별, 용도별, 유통 채널별 예측(2024-2032년)

Global Injectable Cytotoxic Drugs Market will garner a 5.8% CAGR from 2024 to 2032, fueled by advancements in drug formulations and growth in oncology drug development. Innovations in drug formulations, such as ready-to-use injectables and improved delivery systems, enhance treatment efficiency and patient compliance. Furthermore, the continuous development of new oncology drugs expands the range of available therapies, offering more targeted and effective treatment options for various cancers. These advancements improve therapeutic outcomes and stimulate market growth by addressing evolving clinical needs and increasing patient access to advanced treatments.

For instance, in June 2023, the US FDA approved Amneal Pharmaceuticals' PEMRYDI RTU, a ready-to-use oncology injectable. It is indicated for initial treatment of metastatic non-squamous non-small cell lung cancer, used with pembrolizumab and platinum chemotherapy in patients without specific genomic mutations. The approval highlights the ongoing innovation in injectable cytotoxic drugs, particularly for complex cancer treatments. It underscores a growing focus on personalized medicine and combination therapies, which could drive increased demand for advanced injectable cytotoxic drugs and contribute to market growth and diversification.

The injectable cytotoxic drugs industry is classified based on class, application, distribution channel, and region.

The vinca alkaloids segment will encounter a marked upturn through 2032 due to their established efficacy in treating various cancers, including leukemia and lymphoma. These drugs, such as vincristine and vinblastine, work by disrupting cancer cell division, making them essential in chemotherapy regimens. Their well-documented success and continued use in oncology contribute to their dominant market position. The ongoing development of new formulations and combination therapies further supports the growth and prominence of the vinca alkaloids segment.

The rheumatoid arthritis segment will observe a noteworthy surge between 2024 and 2032, driven by the high prevalence of this chronic inflammatory condition and the effectiveness of cytotoxic drugs in managing severe cases. Injectable cytotoxic drugs, such as methotrexate, are crucial in reducing inflammation and slowing disease progression, providing significant relief for patients. The growing awareness of treatment options and increasing adoption of these therapies in rheumatoid arthritis management drive the segment's prominence, contributing to its leading market position.

Asia Pacific injectable cytotoxic drugs market will achieve a decent share from 2024 to 2032, attributed to rapidly growing healthcare infrastructure and increasing incidence of cancer. The region's expanding population, rising awareness of cancer treatments, and substantial investments in healthcare technology drive demand for advanced injectable cytotoxic drugs. Additionally, the presence of major pharmaceutical companies and robust R&D activities further support market growth. Asia Pacific's dynamic healthcare landscape and focus on improving cancer care position it as a pivotal contributor to the global injectable cytotoxic drugs industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of cancer and rheumatoid arthritis
    • 3.2.1.2 Growing regulatory approvals for injectable cytotoxic drugs
    • 3.2.1.3 Increasing investments for the development of precision oncology therapies
    • 3.2.1.4 Rapid increase in cancer care facilities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High drug development cost
    • 3.2.2.2 Presence of strong alternative therapies
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antimetabolites
• 5.3 Vinca alkaloids
• 5.4 Taxanes
• 5.5 Anthracyclines
• 5.6 Platinum compounds
• 5.7 Alkylating agents
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital pharmacies
• 6.3 Retail pharmacies
• 6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Rheumatoid arthritis
• 7.4 Multiple sclerosis
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbvie Inc
• 9.2 Accord Healthcare, Inc.
• 9.3 Amgen, Inc.
• 9.4 Baxter International Inc.
• 9.5 Bristol-Myers Squibb Company
• 9.6 Eli Lilly and Company
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 Fresenius Kabi AG
• 9.9 Johnson and Johnson Services Inc.
• 9.10 Merck & Co. Inc.
• 9.11 Novartis AG
• 9.12 Pfizer, Inc.
• 9.13 Sanofi
• 9.14 Takeda Pharmaceutical Company Limited
• 9.15 Teva Pharmaceutical Industries Ltd.